Jaguar Health, Inc. — Form 8-K
Filed October 5, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 78/100
What the filing says
Jaguar Health declared a special stock dividend of Series R Convertible Preferred Stock (2,325,000 shares authorized) to common shareholders and certain warrant holders as of record date October 13, 2026. Each Series R share converts to 5 common shares on November 2, 2026, creating ~11.6M conversion shares. The company simultaneously amended two $12M royalty agreements (Uptown Capital, Streeterville Capital) to raise minimum monthly payments to $750K effective January 1, 2027, and extended maturity of a $6.2M secured note to January 1, 2027.
Why this rating
Massive dilution event (83%+ new shares on ~$3.8M market cap) plus increased debt service obligations materially threaten company survival; highly significant relative to tiny company size.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
before filing · preread $4.20 ▼ 0.25% | at our read · unknown $4.21 | +10 min · unknown $4.23 ▲ 0.48% | +30 min · unknown $5.66 ▲ 34.44% | +1 hr · unknown $5.08 ▲ 20.55% | +4 hrs pending |
The stock had already moved +0.25% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.